VSTM
Verastem, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+52/100
Last price
7.86
▼ 0.14 (1.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
8.00
Prev close
8.00
Day high
8.18
Day low
7.70
Volume
2.51M
Market cap
$701.87M
P/E (TTM)
—
52W range
3.43 – 10.82
Day trading desk
Gap from prior close
0.00%
Prior close 8.00
VWAP
7.80
+0.74% from price
Relative volume
2.08×
Unusually busy
Session range
23.61%
7.20 – 8.90
Position in range
39%
Mid range
ATR (14D)
0.50
6.34% of price
Prior day high
8.10
PDH
Prior day low
7.52
PDL
Bid / ask spread
—
Quote not published
Session volume
4.77M
Avg 2.29M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.15%
-4.1%
1M
-5.49%
-6.6%
3M
+52.56%
+48.0%
6M
+42.20%
+24.0%
YTD
+0.39%
-13.9%
1Y
-10.92%
-27.3%
3Y
-4.67%
-86.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VSTM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+332.88K
Net buying
Buy transactions
8
360.00K shares
Sell transactions
5
27.12K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
988.05K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 21, 26 | CALKINS DANIEL Chief Financial Officer |
SELL | 55 | $424 | Direct |
| Aug 3, 26 | PATERSON DANIEL W Chief Executive Officer |
SELL | 1.30K | $7.57K | Direct |
| Jun 22, 26 | CALKINS DANIEL Chief Financial Officer |
SELL | 4.09K | $17.09K | Direct |
| Jun 22, 26 | PATERSON DANIEL W Chief Executive Officer |
SELL | 20.87K | $87.24K | Direct |
| May 21, 26 | JOHNSON JOHN H. Director |
STOCK | 36.00K | $0 | Direct |
| May 21, 26 | BAILEY MICHAEL P Director |
STOCK | 108.00K | $0 | Direct |
| May 21, 26 | ROWINSKY ERIC K. Director |
STOCK | 36.00K | $0 | Direct |
| May 21, 26 | STUGLIK BRIAN M Director |
STOCK | 36.00K | $0 | Direct |
| May 21, 26 | KAPUR ANIL Director |
STOCK | 36.00K | $0 | Direct |
| May 21, 26 | ROBERTSON MICHELLE Director |
STOCK | 36.00K | $0 | Direct |
| May 21, 26 | BUNN PAUL A Director |
STOCK | 36.00K | $0 | Direct |
| May 21, 26 | TOLLEFSON KARIN ANNA Director |
STOCK | 36.00K | $0 | Direct |
| May 4, 26 | PATERSON DANIEL W Chief Executive Officer |
SELL | 806 | $4.69K | Direct |
| Mar 20, 26 | CALKINS DANIEL Chief Financial Officer |
STOCK | 57 | $327 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BAILEY MICHAEL P |
Director | 108.00K | Stock Award(Grant) |
CALKINS DANIEL |
Chief Financial Officer | 118.01K | Sale |
JOHNSON JOHN H. |
Director | 52.67K | Stock Award(Grant) |
KAPUR ANIL |
Director | 52.67K | Stock Award(Grant) |
PATERSON DANIEL W |
Chief Executive Officer | 589.94K | Sale |
ROBERTSON MICHELLE |
Director | 52.67K | Stock Award(Grant) |
ROS MATTHEW |
Chief Operating Officer | 50.00K | Stock Award(Grant) |
ROWINSKY ERIC K. |
Director | 52.67K | Stock Award(Grant) |
STUGLIK BRIAN M |
Director | 137.15K | Stock Award(Grant) |
TOLLEFSON KARIN ANNA |
Director | 52.67K | Stock Award(Grant) |
Fundamentals
Market cap$701.87M
Enterprise value$649.84M
Revenue (TTM)$87.53M
Gross profit$76.71M
EBITDA$-158.65M
Net income$-202.70M
EPS (TTM)$-2.45
Free cash flow$-103.43M
Total cash$136.35M
Total debt$84.33M
Book value / share$0.93
Shares outstanding90.56M
Float70.50M
Short % of float20.02%
Dividend yield0.00%
Beta (5Y)0.39
Valuation & profitability ratios
Trailing P/E—
Forward P/E-10.33
PEG ratio—
Price / sales—
Price / book8.32
EV / revenue7.43
EV / EBITDA-4.10
Gross margin87.64%
Operating margin-81.62%
Profit margin-231.59%
Return on equity-471.16%
Return on assets-49.59%
Debt / equity168.71
Current ratio2.26
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $30.91M | $10.00M | $0 | $2.60M | +209.1% |
| Operating revenue | $30.91M | $10.00M | $0 | $2.60M | +209.1% |
| Cost of revenue | $5.30M | $0 | $0 | $0 | — |
| Gross profit | $25.62M | $10.00M | $0 | $2.60M | +156.2% |
| Research & development | $114.60M | $81.33M | $61.36M | $50.56M | +40.9% |
| Selling, general & admin | $81.15M | $43.62M | $30.73M | $24.98M | +86.0% |
| Total operating expense | $195.75M | $124.96M | $92.08M | $75.53M | +56.7% |
| Operating income | -$170.13M | -$114.96M | -$92.08M | -$72.94M | -48.0% |
| Net interest income | $2.93M | -$413.00K | $2.08M | -$922.00K | +809.4% |
| Pre-tax income | -$209.47M | -$130.45M | -$87.37M | -$73.81M | -60.6% |
| Tax provision | $0 | $185.00K | $0 | $0 | -100.0% |
| Net income | -$209.47M | -$130.64M | -$87.37M | -$73.81M | -60.3% |
| Net income to common | -$209.47M | -$130.64M | -$87.37M | -$73.81M | -60.3% |
| Basic EPS | -3.02 | -3.66 | -3.96 | -4.57 | +17.5% |
| Diluted EPS | -3.02 | -3.66 | -3.96 | -4.57 | +17.5% |
| EBIT | -$208.33M | -$125.89M | -$83.23M | -$71.67M | -65.5% |
| EBITDA | -$207.60M | -$125.86M | -$83.17M | -$71.56M | -64.9% |
| Basic shares | 69.31M | 35.71M | 22.05M | 16.14M | +94.1% |
| Diluted shares | 69.31M | 35.71M | 22.05M | 16.14M | +94.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $204.99M | $88.82M | $77.91M | $74.93M | — | +130.8% |
| Cash & short-term investments | $213.80M | $88.82M | $137.13M | $87.89M | — | +140.7% |
| Accounts receivable | — | $200.00K | $0 | $31.00K | $516.00K | — |
| Inventory | $1.83M | $0 | — | — | — | — |
| Total current assets | $223.41M | $94.96M | $143.68M | $92.87M | — | +135.3% |
| Property, plant & equipment | $491.00K | $1.44M | $1.21M | $1.88M | — | -65.8% |
| Goodwill & intangibles | $16.43M | $0 | — | — | — | — |
| Total assets | $246.44M | $101.54M | $149.72M | $95.05M | — | +142.7% |
| Total current liabilities | $72.27M | $30.97M | $26.38M | $21.66M | — | +133.3% |
| Current debt | $5.30M | — | — | $275.00K | — | — |
| Long-term debt | $81.33M | $40.72M | $40.09M | $24.53M | — | +99.7% |
| Total debt | $87.17M | $42.25M | $41.56M | $27.07M | — | +106.3% |
| Total liabilities | $189.25M | $130.43M | $92.34M | $47.66M | — | +45.1% |
| Retained earnings | -$1.16B | -$955.53M | -$824.89M | -$737.52M | — | -21.9% |
| Shareholder equity | $57.20M | -$28.89M | $57.37M | $47.39M | — | +298.0% |
| Working capital | $151.15M | $63.99M | $117.30M | $71.21M | — | +136.2% |
| Net tangible assets | $40.77M | -$28.89M | $57.37M | $47.39M | — | +241.1% |
| Shares issued | 77.74M | 44.78M | 25.28M | 16.71M | — | +73.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$209.47M | -$130.64M | -$87.37M | -$73.81M | — | -60.3% |
| Depreciation & amortisation | $728.00K | $26.00K | $62.00K | $118.00K | — | +2,700.0% |
| Stock-based compensation | $9.40M | $7.34M | $5.86M | $6.05M | — | +28.1% |
| Change in working capital | $26.00M | $3.72M | -$957.00K | $3.90M | — | +599.4% |
| Operating cash flow | -$137.51M | -$104.77M | -$86.46M | -$63.67M | — | -31.2% |
| Capital expenditure | -$9.62M | -$28.00K | — | — | -$196.00K | -34,271.4% |
| Investing cash flow | -$9.62M | $59.97M | -$44.45M | $66.19M | — | -116.0% |
| Share buybacks | — | — | — | — | -$925.00K | — |
| Dividends paid | — | — | — | $0 | $0 | — |
| Financing cash flow | $263.31M | $54.78M | $134.19M | $51.78M | — | +380.6% |
| Free cash flow | -$147.13M | -$104.80M | -$86.46M | -$63.67M | — | -40.4% |
| End cash position | $205.23M | $89.06M | $79.08M | $75.79M | — | +130.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $40.08M | $18.67M | $17.54M | $11.24M | $2.14M | — | +114.7% |
| Operating revenue | $40.08M | $18.67M | $17.54M | $11.24M | $2.14M | — | +114.7% |
| Cost of revenue | $4.04M | $3.05M | $2.89M | $1.96M | $446.00K | — | +32.4% |
| Gross profit | $36.04M | $15.62M | $14.64M | $9.28M | $1.69M | — | +130.7% |
| Research & development | $41.34M | $38.22M | $31.67M | $28.99M | $24.79M | — | +8.2% |
| Selling, general & admin | $27.41M | $22.30M | $24.44M | $21.01M | $20.67M | — | +22.9% |
| Total operating expense | $68.75M | $60.52M | $56.12M | $50.00M | $45.45M | — | +13.6% |
| Operating income | -$32.71M | -$44.90M | -$41.48M | -$40.72M | -$43.76M | — | +27.1% |
| Net interest income | $748.00K | $915.00K | $689.00K | $863.00K | $610.00K | — | -18.3% |
| Pre-tax income | -$33.86M | -$36.59M | -$32.92M | -$98.52M | -$25.93M | — | +7.5% |
| Tax provision | $816.00K | — | — | — | $0 | — | — |
| Net income | -$34.67M | -$36.59M | -$32.92M | -$98.52M | -$25.93M | — | +5.2% |
| Net income to common | -$34.67M | -$36.59M | -$32.92M | -$98.52M | -$25.93M | — | +5.2% |
| Basic EPS | -0.35 | -0.37 | — | -1.35 | -0.39 | -0.96 | +5.4% |
| Diluted EPS | -0.35 | -0.46 | — | -1.35 | -0.62 | -0.96 | +23.9% |
| EBIT | -$33.50M | -$36.21M | -$32.50M | -$98.20M | -$25.72M | — | +7.5% |
| EBITDA | -$33.22M | -$35.93M | -$32.20M | -$97.91M | -$25.59M | — | +7.6% |
| Basic shares | 100.12M | 98.29M | — | 73.16M | 66.14M | 54.17M | +1.9% |
| Diluted shares | 100.12M | 99.15M | — | 73.16M | 74.04M | 54.17M | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $136.35M | $165.55M | $204.99M | $137.71M | $164.32M | — | -17.6% |
| Cash & short-term investments | $136.35M | $181.68M | $213.80M | $137.71M | $164.32M | — | -24.9% |
| Accounts receivable | $28.87M | $10.16M | — | $6.72M | $2.08M | $200.00K | +184.2% |
| Inventory | $2.40M | $2.29M | $1.83M | $1.79M | $1.17M | — | +4.8% |
| Total current assets | $176.16M | $202.90M | $223.41M | $154.06M | $174.27M | — | -13.2% |
| Property, plant & equipment | $2.63M | $2.79M | $491.00K | $750.00K | $984.00K | — | -6.0% |
| Goodwill & intangibles | $15.87M | $16.15M | $16.43M | $16.70M | $15.64M | — | -1.7% |
| Total assets | $206.51M | $227.81M | $246.44M | $176.85M | $196.26M | — | -9.3% |
| Total current liabilities | $78.13M | $66.84M | $72.27M | $59.71M | $50.36M | — | +16.9% |
| Current debt | $5.44M | $5.79M | $5.30M | $4.31M | $3.13M | — | -6.1% |
| Long-term debt | $76.27M | $76.87M | $81.33M | $84.37M | $80.54M | — | -0.8% |
| Total debt | $84.33M | $85.47M | $87.17M | $89.48M | $84.72M | — | -1.3% |
| Total liabilities | $156.53M | $146.03M | $189.25M | $192.38M | $160.21M | — | +7.2% |
| Retained earnings | -$1.24B | -$1.20B | -$1.16B | -$1.13B | -$1.03B | — | -2.9% |
| Shareholder equity | $49.99M | $81.78M | $57.20M | -$15.53M | $36.06M | — | -38.9% |
| Working capital | $98.03M | $136.06M | $151.15M | $94.34M | $123.91M | — | -28.0% |
| Net tangible assets | $34.12M | $65.63M | $40.77M | -$32.23M | $20.42M | — | -48.0% |
| Shares issued | 90.48M | 87.84M | 77.74M | 66.75M | 61.52M | — | +3.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$34.67M | -$36.59M | -$32.92M | -$98.52M | -$25.93M | +5.2% |
| Depreciation & amortisation | $280.00K | $279.00K | $298.00K | $292.00K | $128.00K | +0.4% |
| Stock-based compensation | $3.43M | $2.05M | $2.02M | $2.18M | $3.41M | +67.6% |
| Change in working capital | -$12.87M | -$8.57M | $10.25M | $2.86M | $8.62M | -50.3% |
| Operating cash flow | -$43.91M | -$52.12M | -$29.95M | -$36.22M | -$32.66M | +15.7% |
| Capital expenditure | — | — | -$1.34M | — | — | — |
| Investing cash flow | $16.25M | -$16.02M | -$1.34M | -$8.28M | $0 | +201.5% |
| Financing cash flow | -$1.54M | $28.69M | $98.58M | $17.88M | $79.42M | -105.4% |
| Free cash flow | -$43.91M | -$52.12M | -$31.30M | -$44.49M | -$32.66M | +15.7% |
| End cash position | $136.59M | $165.79M | $205.23M | $137.95M | $164.56M | -17.6% |
Options analytics
Put / call volume
0.50
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
3.00
-61.3% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
1.01K
Contracts, this expiry
Put volume
502
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
3.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.45 | -0.31 | +30.6% |
| Mar 2026 | -0.47 | -0.43 | +7.9% |
| Dec 2025 | -0.50 | -0.46 | +7.5% |
| Sep 2025 | -0.61 | -0.54 | +11.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.43 | 2 | $29.13M | +159.1% |
| Next quarter | -0.43 | 2 | $33.57M | +91.5% |
| Current year | -1.80 | 1 | $116.41M | +276.6% |
| Next year | -0.75 | 1 | $181.10M | +55.6% |
Analyst targets & ownership
Mean target$14.67
High target$18.00
Low target$11.00
Implied upside86.60%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy1 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders1.09%
Held by institutions110.94%
Institutions holding207
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.88
-0.27% from price
SMA 20
7.76
-0.14% from price
SMA 50
7.24
+7.02% from price
SMA 100
5.90
+33.29% from price
SMA 200
6.03
+28.43% from price
EMA 12
7.83
+0.33% from price
EMA 26
7.66
+2.65% from price
EMA 50
7.21
+9.09% from price
RSI (14)
52.1
Neutral
MACD (12,26,9)
0.18
Hist -0.05
ATR (14)
0.50
6.43% of price
Realised vol 30D
49.8%
Annualised
Bollinger upper
8.33
20, 2σ
Bollinger lower
7.19
20, 2σ
50 / 200 cross
Golden
7.24 vs 6.03
Trend bias
Above 200
+28.43%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.14
More volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
49.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-67.6%
Peak to trough
Max drawdown 5Y
-94.3%
Peak to trough
ATR 14
0.50
6.43% of price
Beta (reported)
0.39
5Y monthly, from filing
Short interest
Shares short
18.03M
Prior 18.91M
Change vs prior
-4.7%
Shorts covering
% of float
20.02%
Heavily shorted
% of shares out
19.91%
Against total outstanding
Days to cover
8.1
Crowded exit
Float
70.50M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 5, 26 | BTIG | MAINTAINED | Buy | Buy |
| Sep 17, 26 | Wolfe Research | INITIATED | — | Outperform |
| Sep 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 2, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 24, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 23, 26 | Jefferies | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:12
Split dateJun 1, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-07
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-17
Offering Registrations
S-8 · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-26
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-09
Headlines
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
Zacks · 23h ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 1d ago
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Business Wire · 5d ago
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Business Wire · 8d ago
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
CNW Group · 9d ago
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Business Wire · 13d ago
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
MarketBeat · 15d ago
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says
MT Newswires · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.